Etiology and treatment of ischaemic stroke in patients with β-thalassemia major

European Journal of Neurology

Volumn 18, Issue 12, 2011, Pages 1426-1428

  Vassilopoulou, S ^a   Anagnostou, E ^a   Paraskevas, G ^a   Spengos, K ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

thalassemia major; Atrial fibrillation; Cardiac siderosis; Dilative cardiomyopathy; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; CLOPIDOGREL; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; APHASIA; ARTICLE; BETA THALASSEMIA; BETA THALASSEMIA MAJOR; BRAIN ISCHEMIA; CARDIOGENIC EMBOLISM; CASE REPORT; CEREBRAL ARTERY DISEASE; CONGESTIVE CARDIOMYOPATHY; EMBOLISM; FEMALE; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMIANOPIA; HEMIPARESIS; HEMIPLEGIA; HUMAN; MALE; PRIORITY JOURNAL; SIDEROSIS; SIDEROTOXIC CARDIOMYOPATHY; THALASSEMIA MAJOR;

ADULT; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; APHASIA; ATRIAL FIBRILLATION; BETA-THALASSEMIA; BLOOD TRANSFUSION; BRAIN ISCHEMIA; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CHELATION THERAPY; COMBINED MODALITY THERAPY; FEMALE; HEMIPLEGIA; HEMOSIDEROSIS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACRANIAL EMBOLISM; MALE; SPLENECTOMY; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 81855183252     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03431.x     Document Type: Article

References (14)

1. Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease. A comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005; 127: 1523-1530.
2. Borgna-Pignatti C, Rugootto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998; 850: 227-231.
3. Hahalis G, Manolis AS, Apostolopoulos D, Alexopoulos D, Vagenakis AG, Zoumbos NC. Right ventricular cardiomyopathy in β-thalassemia major. Eur Heart J 2002; 23: 147-156.
4. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961-1968.
5. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99: 36-43.
6. Karimi M, Khanlari M, Rachmilewitz EA. Cerebrovascular accident in β- thalassemia major (β-TM) and β-thalassemia intermedia (β-TI). Am J Hematol 2007; 83: 77-79.
7. Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8, 860 patients with thalassemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006; 96: 488-491.
8. Taher A, Mehio G, Isma'eel H, Cappelini MD. Stroke in thalassemia: a dilemma. Am J Hematol 2008; 83: 343.
9. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5hours after acute ischemic stroke. A Meta-analysis. Stroke 2009; 40: 2438-2441.
10. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematol Am Soc Hematol Educ Program 2008; 177-185.
11. Manfre L, Giarratano E, Maggio A, Banco A, Vaccaro G, Lagalla R. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. Am J Radiol 1999; 173: 1477-1480.
12. Zafeiriou DI, Pengler M, Gombakis N, et al. Central nervous sytem abnormalities in asymptomatic young patients with Sβ-thalassemia. Ann Neurol 2004; 55: 835-839.
13. Karimi M, Bagheri H, Rastgu F, Rachmilewitz EA. Magnetic resonance imaging to determine the incidence of brain ischemia in patients with beta-thalassemia intermedia. Thromb Haemost 2010; 103: 989-993.
14. Taher AT, Musallam KM, Karimi M, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost 2010; 8: 2152-2158.